Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
|Articles|October 2, 2015
Carolyn Presley on the Implications of Screening on Lung Cancer Care
Author(s)Carolyn Presley
Carolyn Presley discusses the implications of screening on diagnosis and treatment of lung cancer.
Advertisement
Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses the implications of screening on diagnosis and treatment of lung cancer.
Advertisement
Related to this article
For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.